Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients

Timothy Yeung; Catriona McLean; David M Kaye; Angeline Leet; Hitesh C Patel; Peter Bergin; Caitlin Cheshire; James L Hare; Andrew J Taylor; Sarah Gutman

doi:10.1016/j.jaccao.2022.07.013

Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients

JACC CardioOncol. 2022 Dec 20;4(5):717-721. doi: 10.1016/j.jaccao.2022.07.013. eCollection 2022 Dec.

Authors

Timothy Yeung¹, Catriona McLean¹, David M Kaye^{1

2}, Angeline Leet¹, Hitesh C Patel¹, Peter Bergin¹, Caitlin Cheshire¹, James L Hare^{1

2}, Andrew J Taylor^{1

2}, Sarah Gutman^{1

2}

Affiliations

¹ Alfred Hospital, Melbourne, Victoria, Australia.
² Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

No abstract available

Keywords: ACR, acute cellular rejection; CNI, calcineurin inhibitor; CTLA-4, cytotoxic T-lymphocyte-associated antigen-4; EMB, endomyocardial biopsy; ICI, immune checkpoint inhibitor; ISHLT, International Society for Heart and Lung Transplantation; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro–B-type natriuretic peptide; PD-1, programmed cell death protein-1; PET, positron emission tomography; SOT, solid organ transplant; TTE, transthoracic echocardiogram; heart failure; immunotherapy; mTOR, mammalian target of rapamycin; myocarditis.

Publication types

Review